13:53 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting IRAK1 or its activator PIN1 could help treat radiotherapy-resistant, p53-mutant head and neck cancers and other cancers. In patients with...
20:31 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting PIN1 could help treat pancreatic ductal adenocarcinoma (PDAC). In patients, PIN1 levels were higher in tumor samples than in adjacent normal tissue samples...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1)

Cancer INDICATION: Cancer In vitro studies identified a cell-permeable peptide inhibitor of PIN1 that could help treat cancer. Screening of a library of analogs of a PIN1-inhibiting peptide in a cell-free PIN1-binding assay identified a...
08:00 , Nov 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Nonalcoholic steatohepatitis (NASH) Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1) Mouse studies suggest inhibiting PIN1 could help treat and prevent NASH. In mice fed...
07:00 , Apr 26, 2012 |  BC Innovations  |  Targets & Mechanisms

TAU's cease and de-cis-t letter

Although it is well established that phosphorylated microtubule-associated protein-t contributes to the pathology of Alzheimer's disease, antibodies against the target have so far been ineffective and have thus been relegated to research-only use. Now, researchers...
07:00 , Apr 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Phosphorylated-t 231 (p-t 231) In vitro and mouse studies identified antibodies against the cis conformation of p-t 231 that could help treat...
08:00 , Feb 17, 2011 |  BC Innovations  |  Tools & Techniques

Engineering protein stability

Two American teams have proposed distinct strategies to improve the stability of recombinant proteins. The techniques could be used to increase the manufacturing yield, shelf life and potentially the duration of efficacy of biologics, including...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); amyotrophic lateral sclerosis (ALS); Parkinson's disease (PD) Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1) A study in rat neurons suggests that inhibiting...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Protein (peptidylprolyl cis/trans isomerase) NIMA-interacting 1 (PIN1); BCL2-associated X protein (BAX) Studies in cell culture suggest that inhibiting PIN1 could...
08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cancer Breast cancer Notch homolog 1 translocation-associated (Drosophila) (NOTCH1); protein (peptidylprolyl cis/trans isomerase) NIMA-interacting 1 (PIN1) Studies in mice and...